1. What Happened? : Orum Therapeutics Q2 Earnings Analysis

Orum Therapeutics recorded zero revenue, an operating loss of -99 billion won, and a net loss of -37 billion won in Q2 2025. This significantly fell short of market expectations, disappointing investors.

2. Why These Results? : Reasons for the Underperformance

The main reason for this underperformance is the increase in research and development (R&D) expenses. As a drug development company, R&D investment in clinical trials and pipeline expansion is essential. Orum Therapeutics, in particular, is focusing on developing its innovative TPD² platform technology, prioritizing long-term growth drivers over short-term profitability.

3. What’s Next? : Short-Term and Long-Term Outlook

  • Short-Term Outlook: Increased stock volatility is expected in the short term. There is a possibility of disappointed investors selling their shares, which could lead to a decline in investor sentiment.
  • Long-Term Outlook: In the long term, attention should be paid to the growth potential of the TPD² platform technology. Technology transfer agreements with BMS and Vertex Pharmaceuticals demonstrate Orum Therapeutics’ technological prowess, and there are expectations for additional technology transfers and successful pipeline development in the future.

4. What Should Investors Do? : Investment Strategy Recommendations

  • Long-term investors: Long-term investors who believe in Orum Therapeutics’ growth potential may consider the current stock decline as a buying opportunity.
  • Short-term investors: Short-term investors should be mindful of increased stock volatility and make cautious investment decisions. They should closely monitor pipeline development progress and the status of additional technology transfer agreements.